Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 68,808 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 68,808 shares of the company’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $235.95, for a total transaction of $16,235,247.60. Following the completion of the transaction, the director owned 357,567 shares in the company, valued at approximately $84,367,933.65. The trade was a 16.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jazz Pharmaceuticals Trading Up 0.8%

JAZZ stock opened at $245.43 on Wednesday. The company has a market capitalization of $15.75 billion, a PE ratio of 83.48, a P/E/G ratio of 0.44 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 12 month low of $132.10 and a 12 month high of $266.38. The firm’s 50-day moving average is $229.26 and its 200 day moving average is $218.48. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.64.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter last year, the business posted $8.13 EPS. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Sanford C. Bernstein reiterated a “market perform” rating and issued a $220.00 price target on shares of Jazz Pharmaceuticals in a report on Monday. Wells Fargo & Company raised their price objective on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Needham & Company LLC lifted their target price on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. Truist Financial lifted their target price on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Finally, UBS Group upped their target price on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $293.00.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Large investors have recently modified their holdings of the business. Private Advisor Group LLC boosted its stake in shares of Jazz Pharmaceuticals by 193.2% during the third quarter. Private Advisor Group LLC now owns 3,046 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 2,007 shares in the last quarter. Ieq Capital LLC raised its stake in Jazz Pharmaceuticals by 1,149.2% in the third quarter. Ieq Capital LLC now owns 20,625 shares of the specialty pharmaceutical company’s stock worth $4,775,000 after buying an additional 18,974 shares in the last quarter. Focus Advisor Solutions LLC lifted its holdings in Jazz Pharmaceuticals by 75.2% during the third quarter. Focus Advisor Solutions LLC now owns 2,802 shares of the specialty pharmaceutical company’s stock worth $649,000 after buying an additional 1,203 shares during the period. Edgestream Partners L.P. purchased a new stake in Jazz Pharmaceuticals during the third quarter worth $302,000. Finally, HighTower Advisors LLC boosted its position in Jazz Pharmaceuticals by 6.9% during the 3rd quarter. HighTower Advisors LLC now owns 7,268 shares of the specialty pharmaceutical company’s stock valued at $1,683,000 after acquiring an additional 471 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.